Contacted officials regarding the Red Blood Cell Clinical Trial Program and blood safety issues.
2025 · 4th Quarter (Oct 1 - Dec 31)
CERUS CORPORATION
Filed by INNOVATIVE FEDERAL STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- INNOVATIVE FEDERAL STRATEGIES, LLC
- Client
- CERUS CORPORATION
- Filing UUID
- 18a62b90-3460-4f12-848d-cf92a9457de9
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
H.R.4016/S.2572 Department of Defense Appropriations Bill, 2026, Title VI, all provisions related to blood safety. H.R.5304/S.2587 Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, 2026 - Title II, all provisions related to blood safety.
Literal federal measure citations: H.R.4016, S.2572, H.R.5304, S.2587
H.R.3838/S.2296 National Defense Authorization Act, 2026, Title XIV, all provisions related to blood safety.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.